- Email: [email protected]
mNSCLC)
abstracts
Annals of Oncology
Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/ metastatic non-small cell lung cancer (a/mNSCLC)
O.O. Schmalz1, C. Jacob2,3, J. Ammann4, B. Liss1, S. Iivanainen5, M. Kammermann4, J. Koivunen5, M. Giger6, A. Klein4, R.A. Popescu7 1 Department of Haematology, Oncology and Palliative Care, Helios Universit€ atsklinikum Wuppertal, Wuppertal, Germany, 2The Faculty of Business and Law, Lord Ashcroft International Business School, Anglia Ruskin University, Cambridge, UK, 3School of Business, University of Applied Sciences Northwestern Switzerland, Brugg, Switzerland, 4Medical Affairs (Personalised Healthcare and Patient Access), F. Hoffmann-La Roche Ltd, Basel, Switzerland, 5Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland, 6Department of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen and Rorschach, Switzerland, 7Tumor Zentrum Aarau, Hirslanden Klinik Aarau, Aarau, Switzerland Background: Pts with cancer have disease- and treatment-related symptoms. DPM can facilitate outpatient symptom detection and improve clinical practice, pt quality of life and health benefits. We assessed pt/healthcare professional (HCP) adoption and clinical impact of a DPM tool in CIT-treated pts with a/mNSCLC. Methods: Literature research and pt/HCP advisory boards identified factors influencing DPM use and CIT-related symptoms. These were used to develop a drug-/indication-specific CIT pt module for the Kaiku Health DPM platform, encompassing a symptom questionnaire (per National Cancer Institute Common Terminology Criteria for Adverse Events), HCP symptom overview/alerts, direct pt–HCP communication and pt education for mild/moderate symptoms. The DPM tool was tested over 3 months in Switzerland, Finland and Germany (10 clinics; 45 pts; 2Lþ CIT monotherapy). User experience, overall satisfaction and clinical practice impact data from an online survey/HCP interviews were analysed quantitatively/qualitatively. Results: Of the 21 pt/27 HCP online survey respondents, 73% rated themselves as competent/proficient/expert and 85% used the tool at least weekly; 60% for 10 min per week (pts)/day (HCPs). Most agreed that the tool facilitated more focused and efficient communication. Preferred functions by pts and HCPs were drug-specific information and symptom alerts, respectively. The table shows time needed for pt tool introduction and HCP time saved per pt visit. Telephone consultation need decreased for 33% of pts. Continuous monitoring led to earlier CIT symptom management in several pts. Tool expectations were met/exceeded for 89% of HCPs.
xi30 | Clinical Practice
Volume 30 | Supplement 11 | December 2019
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_11/mdz449.039/5675273 by University of New England user on 10 February 2020
85P
abstracts
Annals of Oncology
Table: 85P HCPs, n (%) n ¼ 27
7 (26) 18 (67) 2 (7) 0
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_11/mdz449.039/5675273 by University of New England user on 10 February 2020
Time for pt tool introduction 0 min (none done) < 30 min 30–60 min > 60 min HCP time saved per pt visit 5 min 6–10 min 11–15 min No time saved More time spent Unsure
6 (22) 5 (19) 1 (4) 7 (26) 1 (4) 7 (26)
Conclusion: The DPM tool educated and empowered pts and saved time on symptom reporting. It also improved care quality, efficiency and pt–HCP communication and enabled earlier symptom management, highlighting the contributions of DPM to clinical care. Editorial acknowledgement: Support for third-party writing assistance for this abstract, furnished by Katie Wilson, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Legal entity responsible for the study: F. Hoffmann-La Roche Ltd, Basel, Switzerland. Funding: F. Hoffmann-La Roche Ltd, Basel, Switzerland. Disclosure: O.O. Schmalz: Advisory / Consultancy, Payment planned: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. C. Jacob: Advisory / Consultancy, External consultant to lead the study design, data analysis, and reporting: F. Hoffmann-La Roche Ltd; Nonremunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. J. Ammann: Shareholder / Stockholder / Stock options, Full / Part-time employment: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. B. Liss: Advisory / Consultancy, Payment planned: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. S. Iivanainen: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses, Lecture: Boehringer Ingelheim; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: Kaiku Health; Non-remunerated activity/ies, Thirdparty medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. M. Kammermann: Full / Part-time employment, Part-time contractor: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. J. Koivunen: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Takeda; Advisory / Consultancy, Travel / Accommodation / Expenses: Faron; Advisory / Consultancy, Travel / Accommodation / Expenses: Kaiku Health; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. M. Giger: Honoraria (self): F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. A. Klein: Shareholder / Stockholder / Stock options, Full / Part-time employment: F. HoffmannLa Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche. R.A. Popescu: Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Merck Sharp & Dohme; Advisory / Consultancy: Merck; Advisory / Consultancy: Lilly; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Vifor Pharma; Advisory / Consultancy: Nutricia; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): AbbVie; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd.
Volume 30 | Supplement 11 | December 2019
doi:10.1093/annonc/mdz449 | xi31
Annals of Oncology
Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/ metastatic non-small cell lung cancer (a/mNSCLC)
O.O. Schmalz1, C. Jacob2,3, J. Ammann4, B. Liss1, S. Iivanainen5, M. Kammermann4, J. Koivunen5, M. Giger6, A. Klein4, R.A. Popescu7 1 Department of Haematology, Oncology and Palliative Care, Helios Universit€ atsklinikum Wuppertal, Wuppertal, Germany, 2The Faculty of Business and Law, Lord Ashcroft International Business School, Anglia Ruskin University, Cambridge, UK, 3School of Business, University of Applied Sciences Northwestern Switzerland, Brugg, Switzerland, 4Medical Affairs (Personalised Healthcare and Patient Access), F. Hoffmann-La Roche Ltd, Basel, Switzerland, 5Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland, 6Department of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen and Rorschach, Switzerland, 7Tumor Zentrum Aarau, Hirslanden Klinik Aarau, Aarau, Switzerland Background: Pts with cancer have disease- and treatment-related symptoms. DPM can facilitate outpatient symptom detection and improve clinical practice, pt quality of life and health benefits. We assessed pt/healthcare professional (HCP) adoption and clinical impact of a DPM tool in CIT-treated pts with a/mNSCLC. Methods: Literature research and pt/HCP advisory boards identified factors influencing DPM use and CIT-related symptoms. These were used to develop a drug-/indication-specific CIT pt module for the Kaiku Health DPM platform, encompassing a symptom questionnaire (per National Cancer Institute Common Terminology Criteria for Adverse Events), HCP symptom overview/alerts, direct pt–HCP communication and pt education for mild/moderate symptoms. The DPM tool was tested over 3 months in Switzerland, Finland and Germany (10 clinics; 45 pts; 2Lþ CIT monotherapy). User experience, overall satisfaction and clinical practice impact data from an online survey/HCP interviews were analysed quantitatively/qualitatively. Results: Of the 21 pt/27 HCP online survey respondents, 73% rated themselves as competent/proficient/expert and 85% used the tool at least weekly; 60% for 10 min per week (pts)/day (HCPs). Most agreed that the tool facilitated more focused and efficient communication. Preferred functions by pts and HCPs were drug-specific information and symptom alerts, respectively. The table shows time needed for pt tool introduction and HCP time saved per pt visit. Telephone consultation need decreased for 33% of pts. Continuous monitoring led to earlier CIT symptom management in several pts. Tool expectations were met/exceeded for 89% of HCPs.
xi30 | Clinical Practice
Volume 30 | Supplement 11 | December 2019
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_11/mdz449.039/5675273 by University of New England user on 10 February 2020
85P
abstracts
Annals of Oncology
Table: 85P HCPs, n (%) n ¼ 27
7 (26) 18 (67) 2 (7) 0
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_11/mdz449.039/5675273 by University of New England user on 10 February 2020
Time for pt tool introduction 0 min (none done) < 30 min 30–60 min > 60 min HCP time saved per pt visit 5 min 6–10 min 11–15 min No time saved More time spent Unsure
6 (22) 5 (19) 1 (4) 7 (26) 1 (4) 7 (26)
Conclusion: The DPM tool educated and empowered pts and saved time on symptom reporting. It also improved care quality, efficiency and pt–HCP communication and enabled earlier symptom management, highlighting the contributions of DPM to clinical care. Editorial acknowledgement: Support for third-party writing assistance for this abstract, furnished by Katie Wilson, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Legal entity responsible for the study: F. Hoffmann-La Roche Ltd, Basel, Switzerland. Funding: F. Hoffmann-La Roche Ltd, Basel, Switzerland. Disclosure: O.O. Schmalz: Advisory / Consultancy, Payment planned: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. C. Jacob: Advisory / Consultancy, External consultant to lead the study design, data analysis, and reporting: F. Hoffmann-La Roche Ltd; Nonremunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. J. Ammann: Shareholder / Stockholder / Stock options, Full / Part-time employment: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. B. Liss: Advisory / Consultancy, Payment planned: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. S. Iivanainen: Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses, Lecture: Boehringer Ingelheim; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: Kaiku Health; Non-remunerated activity/ies, Thirdparty medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. M. Kammermann: Full / Part-time employment, Part-time contractor: F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. J. Koivunen: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Takeda; Advisory / Consultancy, Travel / Accommodation / Expenses: Faron; Advisory / Consultancy, Travel / Accommodation / Expenses: Kaiku Health; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. M. Giger: Honoraria (self): F. Hoffmann-La Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd. A. Klein: Shareholder / Stockholder / Stock options, Full / Part-time employment: F. HoffmannLa Roche Ltd; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche. R.A. Popescu: Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Merck Sharp & Dohme; Advisory / Consultancy: Merck; Advisory / Consultancy: Lilly; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Vifor Pharma; Advisory / Consultancy: Nutricia; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): AbbVie; Non-remunerated activity/ies, Third-party medical writing assistance, furnished by Katie Wilson, PhD, of Health Interactions: F. Hoffmann-La Roche Ltd.
Volume 30 | Supplement 11 | December 2019
doi:10.1093/annonc/mdz449 | xi31